Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Non-Current Deffered Revenue (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Non-Current Deffered Revenue for 7 consecutive years, with $745000.0 as the latest value for Q4 2025.

  • Quarterly Non-Current Deffered Revenue fell 29.52% to $745000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $745000.0 through Dec 2025, down 29.52% year-over-year, with the annual reading at $745000.0 for FY2025, 29.52% down from the prior year.
  • Non-Current Deffered Revenue for Q4 2025 was $745000.0 at 4D Molecular Therapeutics, down from $835000.0 in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $11.7 million in Q1 2021, with the low at $219000.0 in Q2 2025.
  • Average Non-Current Deffered Revenue over 5 years is $1.7 million, with a median of $1.1 million recorded in 2022.
  • The sharpest move saw Non-Current Deffered Revenue plummeted 84.94% in 2022, then soared 55.61% in 2024.
  • Over 5 years, Non-Current Deffered Revenue stood at $2.5 million in 2021, then tumbled by 56.8% to $1.1 million in 2022, then decreased by 9.67% to $972000.0 in 2023, then grew by 8.74% to $1.1 million in 2024, then dropped by 29.52% to $745000.0 in 2025.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $745000.0, $835000.0, and $219000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.